HealthEquity, Inc. (HQY)
HealthEquity, Inc. (HQY) is a healthcare company (health information services) based in the United States. The share price is $102.30, down 2.18% on the day, which values the company at $8.46B. Price as of 17 Nov 2026, 19:13 UTC, from Yahoo Finance.
Key facts
- Share price
- $102.30−2.18% today
- Market value
- $8.46B
- P/E ratio
- 36.9×last 12 months
- Forward P/E
- 18.5×
- Funk Score
- 78/100
- Against its own history
- Well below its usual priceusual price $160.11
- 200-week average
- $83.4723% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
HealthEquity, Inc. in more detail
HQY trades at 36.9× its last twelve months' earnings, 18.5× next year's expected earnings, 6.2× sales. Measured against its own history, the price is 36% below what its usual multiples would imply ($160.11) — well below its usual price. It sits 23% above its 200-week average of $83.47.
Over the last five fiscal years HealthEquity, Inc. has compounded revenue 12.4% a year, earnings per share 83.0% a year, free cash flow 19.4% a year. Its Funk Score is 78 out of 100 (financial strength 6.6, profitability 7.9, growth 8.7, value 8.1, each out of 10).
In its favour: Altman Z in the safe zone; Strong Piotroski score.
1 of the superinvestors tracked here hold HQY, including Ron Baron (0.1% of the portfolio).
Superinvestors holding HQY
1 of the investors tracked here report a position in their latest 13F filing.
- Ron Baron Baron Capital (BAMCO)0.10% of portfolio · $62M · trimmed · Q3 2026
Health Care companies of similar size
- Praxis Precision MedicinesPRAX
- Twist BioscienceTWST
- Protagonist TherapeuticsPTGX
- Krystal BiotechKRYS
- 10x GenomicsTXG
- Corcept TherapeuticsCORT
- Rhythm PharmaceuticalsRYTM
- AlkermesALKS
- PACS GroupPACS
- Kiniksa Pharmaceuticals InternationalKNSA
- ImmunityBioIBRX
- CytokineticsCYTK
Side by side:HQY vs TXG (HealthEquity, Inc. vs 10x Genomics)HQY vs CORT (HealthEquity, Inc. vs Corcept Therapeutics)HQY vs KRYS (HealthEquity, Inc. vs Krystal Biotech)HQY vs PTGX (HealthEquity, Inc. vs Protagonist Therapeutics)HQY vs TWST (HealthEquity, Inc. vs Twist Bioscience)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
HealthEquity, Inc. (HQY): questions and answers
What is HQY's P/E ratio?
HealthEquity, Inc. trades at 36.9× its last twelve months' earnings and 18.5× next year's expected earnings. At its fiscal year-ends over the past 9 years the P/E ranged from 34.8× to 118.1×, with a median of 98.9×.
What is HQY's PEG ratio?
HealthEquity, Inc.'s PEG ratio is 1.27 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is HealthEquity, Inc.'s market cap?
HealthEquity, Inc. is valued at $8.46B at a share price of $102.30.
Is HQY overvalued or undervalued?
Against its own history, HQY is well below its usual price: the price is 36% below the $160.11 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is HQY above its 200-week moving average?
Yes. HQY is 22.6% above its 200-week average of $83.47. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is HealthEquity, Inc. growing?
Over the last five fiscal years HealthEquity, Inc.'s revenue grew 12.4% a year and its earnings per share 83.0% a year; over ten years revenue grew 26.3% a year.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “HealthEquity, Inc. (HQY) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/HQY
Underlying data: Yahoo Finance; company filings with the SEC.